Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6903)	7/21/1999 7:01:00 PM
From: biowa	Read Replies (1) \| Respond to of 9719

V1, Isn't this one of the promising IPO companies you were talking about? biowa Biopure Seeks Regulatory Approval To Market Hemopure In South Africa CAMBRIDGE, Mass., July 20 /PRNewswire/ Biopure(R) Corporation has filed an application with South Africa's Medicines Control Council to market Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], the company's investigational oxygen-carrying solution or "oxygen therapeutic. " The proposed product indication is to eliminate or reduce red blood cell transfusions in elective surgeries. Biopure recently completed a multi-center, non-U.S. Phase III clinical trial evaluating the perioperative use of Hemopure in non-cardiac surgery, which included several sites in South Africa. The study results from this clinical trial form the basis for Biopure's marketing application in South Africa. Biopure Corporation, headquartered in Cambridge, Mass., is a leading developer, manufacturer and marketer of oxygen therapeutics. These pharmaceuticals are intravenously administered into the circulatory system to deliver oxygen to the body's tissues. Biopure has developed and manufactures two hemoglobin-based oxygen therapeutic solutions. Hemopure(R), for human use, is being further evaluated in a pivotal Phase III clinical trial in the United States. Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], the only hemoglobin-based oxygen therapeutic approved by the U.S. Food and Drug Administration, is a veterinary product that has been commercially available since March 1998 for the treatment of anemia in dogs, regardless of the cause.